Connor Iapoce

VERVE-102 is targeting the reduction of LDL-C levels among individuals with hyperlipidemia and high lifetime cardiovascular risk.

With regulatory clearance for people aged ≥18 years with diabetes, Dexcom G7 boasts the longest-lasting wearable and most accurate CGM system.

Our Q1 2025 recap for ophthalmology spotlights 5 regulatory updates, 5 key trial announcements, and two episodes of our flagship ophthalmology podcast.

Our Q1 2025 recap for cardiology spotlights 6 regulatory updates, 5 key trial announcements, and top expert perspectives in cardiac care.

Patients hospitalized for STEMI achieved similar outcomes with rivaroxaban as warfarin after three months of follow-up in the RIVAWAR trial.

Patients with PAH saw a 76% reduction in the composite of morbidity and mortality outcomes with sotatercept treatment.

Pulse oximeter bias was less negative in darkly pigmented skin, suggesting a difference in performance across skin pigment categories.

Intravenous iron supplementation was safe but showed mixed improvement in cardiovascular outcomes in the FAIR-HF2 trial at ACC.25.

Dapagliflozin lowered the incidence of all-cause death or worsening of heart failure versus standard care in the DapaTAVI trial at ACC.25.

A secondary analysis of FINEARTS-HF found consistent efficacy of finerenone on heart failure events and cardiovascular death, irrespective of AF status.

Four-year results from SOUL at ACC.25 were the first to test the cardiovascular benefits of an oral GLP-1 RA in high-risk type 2 diabetes.

OAC-naive patients experienced a significantly smaller increase in stroke or systemic embolism with asundexian than apixaban.

A high non-HDL-C to HDL-C ratio was linked to the risk of ischemic heart disease in people with type 2 diabetes.

The pivotal trial investigating sozinibercept combination therapy failed to meet the primary endpoint of mean change in BCVA at 52 weeks.

The IND submission for VERVE-102 was supported by interim data from the dose-escalation portion of the ongoing Heart-2 Phase 1b clinical trial.

The approval expands the indication for vutrisiran, which becomes the first therapeutic approved by the FDA for the treatment of ATTR-CM.

A new systematic review finds IV iron effective for iron non-responders but calls for further studies on the causes of oral iron failure.

AID technology outperformed CGM alone to reduce HbA1c, without increasing hypoglycemia, in adults with insulin-treated type 2 diabetes.

AstraZeneca announced eneboparatide normalized serum calcium with statistical significance at 24 weeks compared with placebo.

If approved, this indication targets the treatment of adult patients with heart failure with a left ventricular ejection fraction of ≥40%.

Anemia was linked to lower waist circumference, lower albumin levels, and treatment regimens in females, but not males.

Food insecurity remained associated with incident CVD after adjustment for socioeconomic factors among participants in the 2000-2020 CARDIA study period.

The novel controlled metabolic accelerator significantly reduced fat-specific body weight but showed no improvements in exercise capacity over 19 weeks.

ATSN-201 gene therapy has previously received Rare Pediatric Disease and Orphan Drug designations from the regulatory agency.

A study of 3 large US cohorts found a higher intake of butter was linked to greater mortality rates, while plant-based oil intake lowered total mortality.

The regulatory agency granted 510(k) clearance to Caristo Diagnostics' image analysis software to aid in coronary artery disease diagnosis.

Topline data from the pivotal Launch-HTN and Advance-HTN trials met primary endpoints, supporting lorundrostat for uncontrolled or resistant hypertension.

The regulatory agency accepted the BLA's filing and assigned a target action date of August 31, 2025.

The pivotal trial showed superior weight loss to placebo at 68 weeks but fell short of ≥25% weight loss initially expected by Novo Nordisk.

With this historic approval, revakinagene taroretcel (ENCELTO) becomes the first and only FDA-approved treatment for MacTel.